Drug
Vegf Inhibitor Ptc299
Vegf Inhibitor Ptc299: highest development phase Phase 1/2, developed by PTC Therapeutics. 2 trial records tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- PTC Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| VEGF inhibitor PTC299 NCT00686842 | Phase 1/2 | Kaposi's Sarcoma |
| VEGF inhibitor PTC299 NCT01158300 | Phase 1 | Brain and Central Nervous System Tumors |
Latest
No recent events.
Follow Vegf Inhibitor Ptc299 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.